Skip to content
Back to news

Palm Therapeutics wins Servier Discovery Award for its work in the life sciences

As a company committed to therapeutic progress to serve patient needs, Servier takes an open and collaborative approach to R&D at every stage of the drug development life cycle, including early-stage discovery.

Our Servier Discovery Award to the California Life Sciences Association (CLSA) FAST program  recognizes the aspiring life-science companies and entrepreneurs who are driving scientific innovation in areas of high unmet need, including hard-to-treat diseases in oncology, neuroscience and immuno-inflammation, as well as those pursuing research in translational medicine, drug development technologies and drug delivery platforms.

We have thus awarded the Servier Discovery Award 2023 to Palm Therapeutics, out of 40 start-up candidates. Palm Therapeutics is helping advance the development of novel therapeutics to address the unmet clinical needs in oncology by pursuing traditionally undruggable targets, such as NRAS, with the first palmitoylation-targeted drugs. While the functional role of palmitoylation has been well established in numerous diseases, methods to selectively drug this modification have been underexplored. Palm was founded with the mission of unlocking the therapeutic potential of this space. Using targeted drug chemistry and a proprietary discovery platform, Palm Therapeutics has enabled palmitoylation-targeted drug development for the first time.

Did you know?

The first Servier FAST Discovery Award was presented in 2022 to Californian start-up F5 Therapeutics.

Photo of two people working together

With start-ups, an open innovation dynamic

Because we believe in the power of research to accelerate innovation, we pursue an open, collaborative R&D dynamic. We see three essential advantages in this: accelerating research time, offering each project the best development framework, and surrounding ourselves with the best partners for each of our projects.

Our presence within the life sciences ecosystem in Boston, as well as the new Spartners incubator at our R&D Institute in Paris-Saclay, are testimony to this.